For weeks, New Yorkers have witnessed the alarming rise of a homegrown version of the coronovirus that has greatly increased the number of cases in the city. City officials have repeatedly warned that the variant may be more contagious and dodge the immune response.
On that second point, at least, they can now breathe easily: both Pfizer-BioNotech and Modern vaccines will effectively prevent death from severe disease and variants, two independent studies suggest.
Antibodies stimulated by those vaccines are slightly less potent in controlling variants than the original form of the virus, both studies found.
“We’re not seeing big differences,” said Michelle Neusenzwig, an immunologist at Rockefeller University in New York and a member of the published team One of studies on Thursday.
Bottom-line? “Get vaccinated,” he said.
Results are based on laboratory experiments with blood samples from a low number of vaccinated people and have not yet been peer reviewed. They are still consistent in a similar fashion, many experts said, and they join a growing body of research that suggests that the two main vaccines in the United States are protective against all variants identified so far Huh.
“The take-home message is that vaccines are going to work against the New York version and the South African version and the UK version,” said Nathan Landau, a virologist at NYU’s Grossman School of Medicine.
- On April 23, advisors from the Disease Control and Prevention Panel voted to take a stand on the Johnson & Johnson Kovid vaccine and recommend adding a label about a highly unusually dangerous potential blood clotting disorder.
- Federal health officials are expected to formally recommend that states should stop.
- The administration of the vaccine ground recently came to the vaccine after reports of the emergence of a rare blood clotting disorder in six women.
- The overall risk of developing the disorder is extremely low. Women between 30 and 39 appear to be at highest risk, with 11.8 cases given per million doses. There have been seven cases per million doses among women between 18 and 49.
- About eight million doses of the vaccine have now been administered. In men and women who are 50 or more, there have been fewer than one case per million doses.
- Johnson & Johnson had also decided to delay the rollout of its vaccine in Europe amid similar concerns, but the EU drug regulator later said the warning label should be added. South Africa was devastated by a more contagious virus variant that suspended the use of the vaccine, but later moved on with it.
Vaccines prompt the body to mount an extended immune response with thousands of types of antibodies and several types of immune cells. A subset of these immune fighters, called neutralizing antibodies, is required to prevent infection. But when neutralizing antibodies are in short supply or even absent, the rest of the immune system can be an adequate defense to prevent serious illness and death.
In both new studies, neutralizing antibodies from vaccinated people was better than thwarting the virus compared to those who developed antibodies by becoming ill with Kovid-19. A direct comparison of two sets of antibodies offered Possible explanation: Antibodies from those vaccinated are widely distributed across parts of the virus, so no mutation has a major impact on their effect – vaccines bet better against variants than immunity to natural infections. is.
Scientists run the city through the city after its initial discovery in November, a version first identified in New York as B.1.526. It accounted for one in four diagnosed cases by November and by 13. April, with nearly half of the cases, a stagnation in the UK, the version bringing B.1.1.7 is also widespread in New York. Together, the two add more than 70 percent of coronovirus cases to the city.
Concern about the variant identified in New York focuses on one form of it, including a mutation that scientists are calling Eq. Eq mutations microscopically alter the size of the virus, making antibodies difficult to target the virus and, as a result, reducing vaccines.
April 24, 2021, 12:53 pm ET
In Second study, Dr. Landau’s team found that Pfizer and Modern vaccines are only slightly less protective against variants that devastated Britain and against variants of variants discovered in New York that do not have Eq mutations.
Several laboratory studies have shown that antibodies induced by Pfizer and Modern vaccines are slightly less potent than the third variant, identified in South Africa, including Eq. Other vaccines worsen. South Africa has suspended the use of the AstraZeneca vaccine following clinical trials, indicating that the vaccine does not prevent the mild or moderate disease that was transmitted there.
“It started as a lower level in terms of immunity already generated,” Dr. Nussenzwig said of the AstraZeneca vaccine. Referring to Pfizer and Modern Shots, he said, “We are very fortunate to have these vaccines in this country compared to the rest of the world.”
Florian Kramer, an immunologist at Mount Sinai’s Icon School of Medicine, who was not involved in the new studies, said he was more concerned about vaccine programs in other countries and not about the variants themselves.
“I’m less worried about the variants than I was two months ago,” he said, but added: “I’m worried about countries that don’t have enough vaccines and who don’t have a vaccine rollout. I’m about America. I’m honestly not worried.
Dr. Landau’s team also tested the monoclonal antibodies used against the treatment variant of Kovid-19. They found that a cocktail of monoclonal antibodies made by Ryzenon worked against variants discovered in New York, as well as against the original virus.
The studies are reassuring, but they indicate that ech mutations are one to watch, said Jessie Bloom, an evolutionary biologist at the Fred Hutchinson Cancer Research Center in Seattle.
“This could certainly be a step toward viruses that become somewhat resistant to infection- and vaccine-mediated immunity,” Dr. Bloom said. “I don’t think this is something that people need to be worried about immediately, but it definitely affects us as important.”
Dr. Bloom led the analysis comparing vaccine-induced antibodies produced by natural infections. They found that the most potent antibodies bind to multiple sites in a major part of the virus. Even though a mutation in this region affects binding in one site, antibodies that target the remaining sites will still be protective.
Vaccine-induced antibodies cover many more sites in this region than natural infections – and are therefore less likely to be affected by mutations in any one site.
The study looked only at antibodies induced by the modern vaccine, but the results are likely to be similar to those for the Pfizer-BioNotech vaccine, he said.
“This could possibly be a good thing because the virus is causing the mutation,” Dr. Bloom said.
Back to top button